Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis - PubMed (original) (raw)
Clinical Trial
. 1990 May 3;322(18):1265-71.
doi: 10.1056/NEJM199005033221803.
Affiliations
- PMID: 2109197
- DOI: 10.1056/NEJM199005033221803
Free article
Clinical Trial
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
T Storm et al. N Engl J Med. 1990.
Free article
Abstract
Progressive bone loss in osteoporosis results from bone resorption in excess of bone formation. We conducted a double-blind study in 66 women with postmenopausal osteoporosis of therapy with etidronate, a diphosphonate compound that reduces bone resorption by inhibiting osteoclastic activity. The patients were randomly assigned in equal numbers to receive oral etidronate (400 mg per day) or placebo for 2 weeks, followed by a 13-week period in which no drugs were given. This sequence was repeated 10 times, for a total of 150 weeks. Daily oral supplementation with calcium and vitamin D was given throughout the study to both groups. Vertebral bone mineral content was measured by dual-photon absorptiometry; spinal radiographs were assessed to identify new vertebral fractures. Vertebral bone mineral content increased significantly (P less than 0.01) after 150 weeks of etidronate therapy (5.3 percent; 95 percent confidence interval, 2.0 to 8.6; n = 20) but decreased with placebo (-2.7 percent; 95 percent confidence interval, -7.3 to 1.9; n = 20). The difference between groups was 8.0 percentage points (P less than 0.01; 95 percent confidence interval, 2.4 to 13.6). The rates of fracture were significantly different for the period from week 60 to week 150 between the etidronate and placebo groups (6 vs. 54 fractures per 100 patient-years; P = 0.023). No adverse clinical, biochemical, or bone histomorphometric effects of treatment were observed. We conclude that at the end of nearly three years, etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content and, after approximately one year of treatment, a significant decrease in the rate of new vertebral fractures.
Comment in
- Etidronate for postmenopausal osteoporosis.
Bockman RS. Bockman RS. N Engl J Med. 1990 Oct 25;323(17):1209-10. doi: 10.1056/NEJM199010253231713. N Engl J Med. 1990. PMID: 2120586 No abstract available.
Similar articles
- Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ, et al. Watts NB, et al. N Engl J Med. 1990 Jul 12;323(2):73-9. doi: 10.1056/NEJM199007123230201. N Engl J Med. 1990. PMID: 2113611 Clinical Trial. - Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T, Kollerup G, Thamsborg G, Genant HK, Sørensen OH. Storm T, et al. J Rheumatol. 1996 Sep;23(9):1560-4. J Rheumatol. 1996. PMID: 8877926 Clinical Trial. - Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Liberman UA, et al. N Engl J Med. 1995 Nov 30;333(22):1437-43. doi: 10.1056/NEJM199511303332201. N Engl J Med. 1995. PMID: 7477143 Clinical Trial. - Critical drug appraisal: etidronate intermittent cyclic therapy for postmenopausal osteoporosis.
Miller PD. Miller PD. Br J Clin Pract. 1996 Jan-Feb;50(1):23-31. Br J Clin Pract. 1996. PMID: 8729598 Review. - [Etidronate].
Inui K, Takaoka K. Inui K, et al. Nihon Rinsho. 2003 Feb;61(2):226-30. Nihon Rinsho. 2003. PMID: 12638212 Review. Japanese.
Cited by
- Broadband ultrasound attenuation of the calcaneus predicts lumbar and femoral neck density in Caucasian women: a preliminary study.
Baran DT, McCarthy CK, Leahey D, Lew R. Baran DT, et al. Osteoporos Int. 1991 Feb;1(2):110-3. doi: 10.1007/BF01880452. Osteoporos Int. 1991. PMID: 1790391 - Spinal fractures during fluoride therapy for osteoporosis: relationship to spinal bone density.
Farley SM, Wergedal JE, Farley JR, Javier GN, Schulz EE, Talbot JR, Libanati CR, Lindegren L, Bock M, Goette MM, et al. Farley SM, et al. Osteoporos Int. 1992 Sep;2(5):213-8. doi: 10.1007/BF01624143. Osteoporos Int. 1992. PMID: 1392258 - Treatment of osteoporosis: current and future.
Stone MD, Hosking DJ. Stone MD, et al. Ann Rheum Dis. 1991 Oct;50(10):663-5. doi: 10.1136/ard.50.10.663. Ann Rheum Dis. 1991. PMID: 1958084 Free PMC article. Review. No abstract available. - Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.
Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM; Research Committee of the British Thoracic Society. Campbell IA, et al. Thorax. 2004 Sep;59(9):761-8. doi: 10.1136/thx.2003.013839. Thorax. 2004. PMID: 15333852 Free PMC article. Clinical Trial. - Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Russell RG, Watts NB, Ebetino FH, Rogers MJ. Russell RG, et al. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. Osteoporos Int. 2008. PMID: 18214569 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical